tiprankstipranks

Sage Therapeutics price target established at JPMorgan

JPMorgan analyst Anupam Rama established a $9 December 2025 price target on shares of Sage Therapeutics (SAGE) while keeping a Neutral rating on the name. The price target accounts for peaks sales of Zurzuvaue in depression nd no platform value given the company’s multiple pipeline setbacks, the analyst tells investors in a research note.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue